Listar por autor UPNA "Zuazo Ibarra, Miren"
Mostrando ítems 1-14 de 14
-
Contribution of systemic T cell immunity to clinical efficacy of anti-PD-L1/PD-1 immunotherapies in lung cancer
Zuazo Ibarra, Miren
(2020)
Tesis doctoral / Doktoretza tesia 
Un alto porcentaje de pacientes con cáncer de pulmón resistentes a terapias convencionales son refractarios a la inmunoterapia con anticuerpos bloqueadores de la interacción PD-L1/PD-1. En la presente tesis doctoral se ha ... -
Early detection of hyperprogressive disease in non-small cell lung cancer by monitoring of systemic T cell dynamics
Arasanz Esteban, Hugo; Zuazo Ibarra, Miren ; Bocanegra Gondán, Ana Isabel; Gato Cañas, María; Martínez Aguillo, Maite; Morilla Ruiz, Idoia (MDPI, 2020)
Artículo / Artikulua
Hyperprogressive disease (HPD) is an adverse outcome of immunotherapy consisting of an acceleration of tumor growth associated with prompt clinical deterioration. The definitions based on radiological evaluation present ... -
Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy
Zuazo Ibarra, Miren ; Gato Cañas, María; Llorente, Noelia; Ibáñez-Vea, María ; Arasanz Esteban, Hugo; Kochan, Grazyna; Escors Murugarren, David (AME Publishing, 2017)
Artículo / Artikulua
Programmed cell death-1 (PD1) has become a significant target for cancer immunotherapy. PD1 and its receptor programmed cell death 1 ligand 1 (PDL1) are key regulatory physiological immune checkpoints that maintain ... -
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity
Edwards, Carolyn J.; Sette, Angelica; Cox, Carl; Di Fiore, Barabara; Wyre, Chris; Sydoruk, Daniela; Yadin, David; Hayes, Philip; Stelter, Szymon; Bartlett, Phillip D.; Zuazo Ibarra, Miren ; García-Granda, María Jesús; Benedetti, Giovanni; Fiaska, Stratonik; Birkett, Neil R.; Teng, Yumin; Enever, Carrie; Arasanz Esteban, Hugo; Bocanegra Gondán, Ana Isabel; Chocarro, Luisa ; Fernández, Gonzalo; Vera García, Ruth; Archer, Bethan; Osuch, Isabelle; Lewandowska, Martyna; Surani, Yasmin M.; Kochan, Grazyna; Escors Murugarren, David; Legg, James; Pierce, Andrew J. (Springer Nature, 2021)
Artículo / Artikulua
Background: improving cancer immunotherapy long-term clinical benefit is a major priority. It has become apparent that multiple axes of immune suppression restrain the capacity of T cells to provide anti-tumour activity ... -
PD-L1 expression in systemic immune cell populations as a potential predictive biomarker of responses to PD-L1/PD-1 blockade therapy in lung cancer
Bocanegra Gondán, Ana Isabel; Fernandez Hinojal, Gonzalo; Zuazo Ibarra, Miren ; Arasanz Esteban, Hugo; Garcia-Granda, María Jesús; Hernandez, Carlos; Ibáñez-Vea, María ; Hernandez-Marin, Berta; Martinez-Aguillo, Maite; Lecumberri, María José; Fernández de Lascoiti, Ángela; Teijeira, Lucía; Morilla, Idoia; Vera García, Ruth; Escors Murugarren, David; Kochan, Grazyna (MDPI, 2019)
Artículo / Artikulua
PD-L1 tumor expression is a widely used biomarker for patient stratification in PD-L1/PD-1 blockade anticancer therapies, particularly for lung cancer. However, the reliability of this marker is still under debate. Moreover, ... -
PD-L1 in systemic immunity: unraveling its contribution to PD-1/PD-L1 blockade immunotherapy
Bocanegra Gondán, Ana Isabel; Blanco, Ester; Fernández Hinojal, Gonzalo; Chocarro, Luisa ; Zuazo Ibarra, Miren (MDPI, 2020)
Artículo / Artikulua
The use of monoclonal antibodies targeting PD-1/PD-L1 axis completely changed anticancer treatment strategies. However, despite the significant improvement in overall survival and progression-free survival of patients ... -
PD1 signal transduction pathways in T cells
Arasanz Esteban, Hugo; Gato Cañas, María; Zuazo Ibarra, Miren ; Ibáñez-Vea, María ; Breckpot, Karine; Kochan, Grazyna; Escors Murugarren, David (Impact Journals, 2017)
Artículo / Artikulua
The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions between cancer cells and T cells are demonstrating ... -
PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity
Gato Cañas, María; Zuazo Ibarra, Miren ; Arasanz Esteban, Hugo; Ibáñez-Vea, María ; Lorenzo, Laura; Fernandez-Hinojal, Gonzalo; Vera García, Ruth; Smerdou, Cristian; Martisova, Eva; Arozarena Martinicorena, Imanol; Wellbrock, Claudia; Llopiz, Diana; Ruiz, Marta; Sarobe, Pablo; Breckpot, Karine; Kochan, Grazyna; Escors Murugarren, David (Elsevier, 2017)
Artículo / Artikulua
PDL1 blockade produces remarkable clinical responses, thought to occur by T cell reactivation through prevention of PDL1-PD1 T cell inhibitory interactions. Here, we find that PDL1 cell-intrinsic signaling protects cancer ... -
Profound reprogramming towards stemness in pancreatic cancer cells as adaptation to AKT inhibition
Arasanz Esteban, Hugo; Hernández, Carlos; Bocanegra Gondán, Ana Isabel; Chocarro, Luisa ; Zuazo Ibarra, Miren (MDPI, 2020)
Artículo / Artikulua
Cancer cells acquire resistance to cytotoxic therapies targeting major survival pathways by adapting their metabolism. The AKT pathway is a major regulator of human pancreatic adenocarcinoma progression and a key pharmacological ... -
A proteomic atlas of lineage and cancer-polarized expression modules in myeloid cells modeling immunosuppressive tumor-infiltrating subsets
Blanco, Ester; Ibáñez-Vea, María ; Hernández, Carlos; Drici, Lylia; Martínez de Morentin Iribarren, Xabier; Gato Cañas, María; Ausín, Karina; Bocanegra Gondán, Ana Isabel; Zuazo Ibarra, Miren ; Chocarro, Luisa ; Arasanz Esteban, Hugo; Fernández Hinojal, Gonzalo; Fernández Irigoyen, Joaquín ; Smerdou, Cristian; Garnica, Maider; Echaide Górriz, Míriam; Fernández Rubio, Leticia; Morente Sancho, Pilar; Ramos-Castellanos, Pablo; Llopiz, Diana; Santamaría, Enrique; Larsen, Martin R.; Escors Murugarren, David; Kochan, Grazyna (MDPI, 2021)
Artículo / Artikulua
Monocytic and granulocytic myeloid-derived suppressor cells together with tumor-infiltrating macrophages constitute the main tumor-infiltrating immunosuppressive myeloid populations. Due to the phenotypic resemblance to ... -
Systemic blood immune cell populations as biomarkers for the outcome of immune checkpoint inhibitor therapies
Hernández, Carlos; Arasanz Esteban, Hugo; Chocarro, Luisa ; Bocanegra Gondán, Ana Isabel; Zuazo Ibarra, Miren (MDPI, 2020)
Artículo / Artikulua
The development of cancer immunotherapy in the last decade has followed a vertiginous rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies are in clinical use ... -
Systemic CD4 immunity: a powerful clinical biomarker for PD-L1/PD-1 immunotherapy
Zuazo Ibarra, Miren ; Arasanz Esteban, Hugo; Bocanegra Gondán, Ana Isabel; Chocarro, Luisa ; Vera García, Ruth (EMBO Press, 2020)
Artículo / Artikulua
The search for non-invasive systemic biomarkers of response to PD-L1/PD-1 blockade immunotherapy is currently a priority in oncoimmunology. In contrast to classical tumor biomarkers, the identification of clinically useful ... -
TNF-α-secreting tumor-infiltrated monocytes play a pivotal role during anti-PD-L1 immunotherapy
Zuazo Ibarra, Miren ; Ridder, Kirsten de; Locy, Hanne; Piccioni, Elisa; Awad, Robin Maximilian; Verhulst, Stefaan; Van Bulck, Mathias; Vlaeminck, Yannick de; Lecoq, Quentin; Reijimen, Eva; Mey, Wout de; Beck, Lien de; Ertveldt, Thomas; Pintelon, Isabel; Timmermans, Jean-Pierre; Escors Murugarren, David; Keyaerts, Marleen; Breckpot, Karine; Goyvaerts, Cleo (Frontiers Media, 2022)
Artículo / Artikulua
Immune checkpoint blockade (ICB) of the PD-1 pathway revolutionized the survival forecast for advanced non-small cell lung cancer (NSCLC). Yet, the majority of PD-L1+ NSCLC patients are refractory to anti-PD-L1 therapy. ... -
Understanding LAG-3 Signaling
Chocarro, Luisa ; Blanco, Ester; Zuazo Ibarra, Miren ; Arasanz Esteban, Hugo; Bocanegra Gondán, Ana Isabel; Fernández Rubio, Leticia; Morente Sancho, Pilar; Fernández Hinojal, Gonzalo; Echaide Górriz, Míriam; Garnica, Maider; Ramos, Pablo; Vera García, Ruth; Kochan, Grazyna; Escors Murugarren, David (MDPI, 2021)
Artículo / Artikulua
Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in immunity and emerged some time ...
